Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acerâs pipeline includes three clinical-stage candidates: EDSIVO⢠(celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; ACER-001 (a fully taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); and osanetant for the treatment of induced Vasomotor Symptoms (iVMS) where Hormone Replacement Therapy (HRT) is likely contraindicated. Acerâs product candidates are believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. Source
No articles found.
Stop the root cause of snoring by going directly after the tongue. ZYPPAH is the o...
Stop the root cause of snoring by going directl...
INmune Bio Inc. is a clinical stage biotechnology company that is developing new i...
INmune Bio Inc. is a clinical stage biotechnolo...
MDisrupt is a Medical Diligence company for the healthtech industry, helping inves...
MDisrupt is a Medical Diligence company for the...
Syros is redefining the power of small molecules to control the expression of gene...
Syros is redefining the power of small molecule...
Join the National Investor Network and get the latest information with your interests in mind.